Journal
The GLP-1 Market Report: August 2026 — Leaders, Deadlines, and What Breaks Next
Released: Last reviewed:
The state of play, one paragraph
August 2026's market is a three-layer structure in open competition. The floor: verified compounded programs at $99–$139 semaglutide and $125–$179 tirzepatide, with bmiMD ($129 semaglutide) lowest month-to-month on the August record, NexLife at $169 tirzepatide month-to-month, and on committed terms the $99 semaglutide pair and the $125–$139 tirzepatide tier. The squeeze: NovoCare's $149 oral tablet — an approved product inside fifty dollars of the compounded floor — applying the class's most interesting pressure. The ceiling that moved: brand injectables at $299–$449 with active promotional mechanics ($199 pen introduction; $299–$399 titration rungs), a fraction of 2021's $1,349 anchor. Above it all, the insured $25–$50 tier remains unbeatable where the doors (T2D, cardiovascular, sleep apnea) open. Dated windows and one regulatory docket item make the next two quarters unusually legible — which is what this report is for.
Computed leaders, with margins
From the current build's category computation: tirzepatide month-to-month — $169 (NexLife, now its standing price) to the Henry/bmiMD $179 tier, a $10 spread, with Eden listing $129 flat below both on October 15, 2026; tirzepatide twelve-month — LumiMeds $125 (upfront-billed, with the census's caveats) over bmiMD/NexLife's monthly-billed $139, a $14 margin buying billing safety; semaglutide month-to-month — bmiMD $129, with Oak's $133 and HealthRX's $133 three-month adjacent; semaglutide twelve-month — the $99 pair (bmiMD, HealthRX), separated only by billing shape; no-commitment overall — the $169–$179 flat tier as a family; with insurance — Ro's concierge, uncontested in category; brand benchmarks — LillyDirect and NovoCare, verified, the rulers everything above is measured against. Margins this thin are the report's quiet finding: the competitive floor has compressed to single-digit-dollar differences, which moves the real differentiation to verification quality, exit terms, and pharmacy transparency — the exact axes our census and verification guides score.
The windows and the docket
August 31, 2026: recorded at the time as a date for NovoCare's $149 oral-tablet tier; on October 15, 2026 NovoCare listed the Wegovy pill by dose — $149 (1.5 mg), $199 (4 mg) and $299 (9 and 25 mg). NexLife's $169 monthly and $139 twelve-month tirzepatide prices are standing prices, not a deadline offer. December 31, 2026: the $199 pen introduction's window closes, resetting new-patient brand semaglutide math to $349 from fill one; LillyDirect's self-pay Zepbound vial savings also end that day. The docket: the FDA's April 30, 2026 proposal (91 FR 23431) not to place tirzepatide, semaglutide or liraglutide on the 503B bulks list — comment period extended to July 30, 2026 (91 FR 38719), no final decision as of October 15, 2026 — worth watching for any language touching the 503A documented-need lane that constitutes today's entire legitimate compounded market. On September 18, 2026 (posted September 22) the FDA issued a warning letter to Empower Pharmacy saying its compounded tirzepatide/niacinamide and semaglutide/cyanocobalamin products "appear to be essentially copies of FDA-approved semaglutide and tirzepatide products" and citing insanitary conditions. Adverse-event reporting (per the FDA, as of May 31, 2026: 990 reports for compounded semaglutide and more than 730 for compounded tirzepatide) remains the statistic regulators cite and the reason this site's verification stack exists. Status distribution across the 37 tracked programs: the brand channels verified; the market's majority at reported or provider-stated pending capture; five-plus structurally unrankable (funnel-gated or start-only) — a distribution whose improvement runs through exactly one mechanism, dated checkout captures, which our capture file exists to collect. Watch-list for the next report: the post-August promo landscape, any 503A-lane regulatory language, orforglipron's approval timeline (the next structural price event), and whether the compounded floor's $99 line holds or breaks under the tablet's pressure. The report updates when the facts do; the dates above are the facts that will.
Questions people ask
What are the best GLP-1 prices right now (August 2026)?
On the August record: bmiMD $129 semaglutide and NexLife $169 tirzepatide month-to-month (on October 15, 2026, Eden listed $99 semaglutide and $129 tirzepatide a month flat); $99 and $125–$139 on committed terms; NovoCare's $149 approved oral tablet; brand injectables $299–$449; insured copays $25–$50 where the T2D/cardiovascular/sleep-apnea doors open. Margins at the floor now run single-digit dollars — verification quality is the real differentiator.
What GLP-1 deadlines matter before the end of 2026?
December 31, 2026: the $199 pen introduction ends (→$349 from fill one) and LillyDirect's self-pay vial savings end. Plus the pending FDA decision on the 503B bulks list (proposed April 30, 2026 not to include tirzepatide, semaglutide or liraglutide; no final decision as of October 15, 2026) — worth watching for any 503A-lane language.
How reliable are the prices in this report?
Every figure carries a printed status: the brand channels are verified; most compounded rows are reported or provider-stated pending our own checkout captures; funnel-gated and start-only programs are recorded but unranked by methodology. The capture file exists to upgrade statuses with dated evidence — including yours.
This article is pricing research, not medical advice. Verify figures at the provider's checkout. Nothing here is medical advice.